

## Consumer Healthcare turnover

Three months ended 30 June 2016

			Total
	£m	CER%	AR%
<b>Turnover</b>			
Wellness	845	8	14
Oral health	539	10	16
Nutrition	161	(5)	(2)
Skin health	145	(1)	2
Total	1,690	7	12

			Total
	£m	CER%	AR%
<b>Turnover</b>			
US	429	9	19
Europe	504	1	7
International	757	9	11
Total	1,690	7	12

Six months ended 30 June 2016

			Total
	£m	CER%	AR%
<b>Turnover</b>			
Wellness	1,770	29	33
Oral health	1,059	8	11
Nutrition	337	(4)	(3)
Skin health	285	7	8
Total	3,451	16	19

			Total
	£m	CER%	AR%
<b>Turnover</b>			
US	869	17	26
Europe	1,048	20	25
International	1,534	13	12
Total	3,451	16	19

**Pharmaceuticals turnover – three months ended 30 June 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,585</b>	<b>-</b>	<b>8</b>	<b>814</b>	<b>6</b>	<b>16</b>	<b>347</b>	<b>(11)</b>	<b>(6)</b>	<b>424</b>	<b>-</b>	<b>8</b>
<i>Anoro Ellipta</i>	46	>100	>100	31	>100	>100	9	>100	>100	6	>100	>100
<i>Arnuity Ellipta</i>	3	>100	>100	3	>100	>100	-	-	-	-	-	-
<i>Avamys/Veramyst</i>	65	2	10	6	(14)	(14)	22	(9)	-	37	13	23
<i>Flixotide/Flovent</i>	136	(20)	(14)	75	(32)	(25)	22	(14)	-	39	8	5
<i>Incruse Ellipta</i>	28	>100	>100	21	>100	>100	6	>100	>100	1	>100	>100
<i>Nucala</i>	20	>100	>100	14	-	-	6	>100	>100	-	-	-
<i>Relvar/Breo Ellipta</i>	146	>100	>100	80	>100	>100	33	63	74	33	93	>100
<i>Seretide/Advair</i>	900	(13)	(6)	487	(7)	1	213	(25)	(20)	200	(11)	(4)
<i>Ventolin</i>	179	6	12	95	9	17	30	4	7	54	2	6
Other	62	(8)	6	2	-	-	6	22	3	54	(14)	3
<b>Cardiovascular, metabolic and urology (CVMU)</b>	<b>236</b>	<b>(5)</b>	<b>3</b>	<b>101</b>	<b>(8)</b>	<b>(1)</b>	<b>78</b>	<b>11</b>	<b>18</b>	<b>57</b>	<b>(16)</b>	<b>(7)</b>
<i>Avodart</i>	178	(14)	(7)	46	(36)	(30)	77	8	17	55	(13)	(8)
<i>Eperzan/Tanzeum</i>	29	>100	>100	28	>100	>100	1	-	>100	-	-	-
Other	29	(7)	4	27	(4)	-	-	-	-	2	<(100)	100
<b>Immuno-inflammation</b>	<b>78</b>	<b>27</b>	<b>39</b>	<b>71</b>	<b>29</b>	<b>39</b>	<b>5</b>	<b>67</b>	<b>67</b>	<b>2</b>	<b>&lt;(100)</b>	<b>100</b>
<i>Benlysta</i>	78	27	39	71	29	39	5	67	67	2	<(100)	-
<b>Other pharmaceuticals</b>	<b>517</b>	<b>(11)</b>	<b>(7)</b>	<b>19</b>	<b>(72)</b>	<b>(69)</b>	<b>135</b>	<b>(7)</b>	<b>-</b>	<b>363</b>	<b>(3)</b>	<b>-</b>
Dermatology	88	(20)	(16)	(1)	(100)	<100	33	(6)	(3)	56	(15)	(8)
<i>Augmentin</i>	134	(10)	(6)	-	(75)	<100	38	(5)	3	96	(12)	(9)
Other anti-bacterials	42	(2)	-	-	(50)	(100)	11	(17)	(8)	31	7	11
Rare diseases	105	1	12	12	(9)	9	33	3	10	60	2	13
Oncology	37	84	95	-	-	-	-	-	-	37	59	68
Other	111	(33)	(34)	8	(85)	(80)	20	(22)	(13)	83	(16)	(21)
<b>Established Products</b>	<b>601</b>	<b>(14)</b>	<b>(8)</b>	<b>162</b>	<b>(12)</b>	<b>(4)</b>	<b>122</b>	<b>(6)</b>	<b>1</b>	<b>317</b>	<b>(18)</b>	<b>(13)</b>
<i>Coreg</i>	30	(3)	3	30	(3)	3	-	-	-	-	-	-
<i>Hepsera</i>	16	(17)	(11)	-	-	-	-	-	-	16	(17)	(11)
<i>Imigran/Imitrex</i>	36	(26)	(22)	17	(41)	(37)	14	(8)	8	5	-	(17)
<i>Lamictal</i>	151	7	14	78	7	16	25	4	9	48	7	14
<i>Lovaza</i>	10	(63)	(58)	10	(63)	(58)	-	-	-	-	-	-
<i>Requip</i>	30	17	30	5	>100	>100	8	-	14	17	6	6
<i>Serevent</i>	22	(12)	(8)	10	(9)	(9)	9	(11)	-	3	(25)	(25)
<i>Seroxat/Paxil</i>	47	-	9	-	-	-	11	11	22	36	(20)	(12)
<i>Valtrex</i>	30	(43)	(35)	4	(33)	(33)	6	(29)	(14)	20	(48)	(39)
<i>Zeffix</i>	28	(19)	(13)	-	-	-	1	-	-	27	(17)	(10)
Other	201	(19)	(16)	8	(40)	(20)	48	(10)	(8)	145	(21)	(18)
	<b>3,017</b>	<b>(5)</b>	<b>1</b>	<b>1,167</b>	<b>(1)</b>	<b>7</b>	<b>687</b>	<b>(7)</b>	<b>(1)</b>	<b>1,163</b>	<b>(9)</b>	<b>(3)</b>
<b>HIV</b>	<b>865</b>	<b>44</b>	<b>55</b>	<b>510</b>	<b>52</b>	<b>65</b>	<b>256</b>	<b>39</b>	<b>48</b>	<b>99</b>	<b>22</b>	<b>27</b>
<i>Combivir</i>	5	(44)	(44)	2	(62)	(59)	1	(37)	(33)	2	(37)	(42)
<i>Epzicom/Kivexa</i>	157	(21)	(15)	56	(22)	(15)	69	(19)	(14)	32	(20)	(17)
<i>Lexiva/Telzir</i>	14	(28)	(22)	7	(31)	(24)	2	(42)	(37)	5	(13)	(9)
<i>Selzentry</i>	30	(10)	(3)	15	(6)	2	11	(21)	(16)	4	21	23
<i>Tivicay</i>	225	43	55	149	45	58	55	40	49	21	45	54
<i>Triumeq</i>	409	>100	>100	271	>100	>100	107	>100	>100	31	>100	>100
<i>Trizivir</i>	4	(43)	(43)	1	(53)	(48)	2	(36)	(32)	1	(48)	(82)
Other	21	44	42	9	(11)	(3)	9	>100	>100	3	47	14
<b>Pharmaceuticals</b>	<b>3,882</b>	<b>2</b>	<b>10</b>	<b>1,677</b>	<b>11</b>	<b>20</b>	<b>943</b>	<b>2</b>	<b>9</b>	<b>1,262</b>	<b>(7)</b>	<b>(1)</b>

**Vaccines turnover – three months ended 30 June 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Rotarix</i>	108	(1)	7	18	(47)	(40)	17	13	13	73	20	30
<i>Synflorix</i>	137	66	78	-	-	-	11	25	37	126	71	83
<i>Fluarix, FluLaval</i>	17	>100	>100	(1)	(75)	(75)	-	-	-	18	64	64
<i>Bexsero</i>	97	>100	>100	31	>100	>100	60	>100	>100	6	25	50
<i>Menveo</i>	47	7	9	34	24	36	5	(43)	(29)	8	-	(27)
<i>Boostrix</i>	96	(7)	-	55	(2)	6	28	(16)	(10)	13	(8)	-
<i>Infanrix, Pediarix</i>	140	(30)	(25)	53	(25)	(17)	64	(26)	(21)	23	(45)	(45)
Hepatitis	130	2	7	56	(12)	(3)	49	24	32	25	-	(4)
<i>Priorix, Priorix Tetra, Varilrix</i>	79	42	50	-	-	-	41	27	38	38	63	66
<i>Cervarix</i>	17	(6)	(6)	1	-	-	8	(22)	(11)	8	12	-
Other	92	(4)	7	11	(17)	(40)	42	25	13	39	(6)	30
	<b>960</b>	<b>11</b>	<b>18</b>	<b>258</b>	<b>(2)</b>	<b>8</b>	<b>325</b>	<b>11</b>	<b>19</b>	<b>377</b>	<b>20</b>	<b>26</b>

**Pharmaceuticals turnover – six months ended 30 June 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>3,003</b>	<b>(1)</b>	<b>4</b>	<b>1,447</b>	<b>4</b>	<b>12</b>	<b>695</b>	<b>(12)</b>	<b>(9)</b>	<b>861</b>	<b>-</b>	<b>4</b>
<i>Anoro Ellipta</i>	79	>100	>100	54	>100	>100	16	>100	>100	9	>100	>100
<i>Arnuity Ellipta</i>	6	>100	>100	6	>100	>100	-	-	-	-	-	-
<i>Avamys/Veramyst</i>	143	5	10	12	(15)	(8)	40	(3)	3	91	13	17
<i>Flixotide/Flovent</i>	289	(12)	(7)	164	(17)	(10)	47	(10)	(4)	78	(1)	-
<i>Incruse Ellipta</i>	50	>100	>100	40	>100	>100	9	>100	>100	1	>100	>100
<i>Nucala</i>	27	>100	100	20	-	-	7	>100	>100	-	-	-
<i>Relvar/Breo Ellipta</i>	257	>100	>100	137	>100	>100	63	71	80	57	>100	>100
<i>Seretide/Advair</i>	1,653	(16)	(11)	826	(12)	(6)	439	(25)	(21)	388	(11)	(8)
<i>Ventolin</i>	358	7	12	187	9	18	61	(2)	2	110	9	8
Other	141	(1)	9	-	-	-	13	6	(5)	127	(3)	9
<b>Cardiovascular, metabolic and urology (CVMU)</b>	<b>420</b>	<b>(9)</b>	<b>(3)</b>	<b>160</b>	<b>(19)</b>	<b>(14)</b>	<b>156</b>	<b>12</b>	<b>17</b>	<b>104</b>	<b>(15)</b>	<b>(11)</b>
<i>Avodart</i>	310	(20)	(16)	53	(60)	(57)	154	11	17	103	(13)	(12)
<i>Eperzan/Tanzeum</i>	54	>100	>100	53	>100	>100	1	>100	>100	-	-	-
Other	56	(2)	10	54	2	8	1	>100	-	1	>(100)	100
<b>Immuno-inflammation</b>	<b>143</b>	<b>15</b>	<b>23</b>	<b>130</b>	<b>14</b>	<b>23</b>	<b>10</b>	<b>29</b>	<b>43</b>	<b>3</b>	<b>-</b>	<b>-</b>
<i>Benlysta</i>	143	24	34	130	25	34	10	29	43	3	-	-
<b>Other pharmaceuticals</b>	<b>1,097</b>	<b>(17)</b>	<b>(15)</b>	<b>44</b>	<b>(78)</b>	<b>(77)</b>	<b>292</b>	<b>(21)</b>	<b>(17)</b>	<b>761</b>	<b>-</b>	<b>2</b>
Dermatology	184	(16)	(14)	7	(68)	(68)	71	(3)	-	106	(14)	(12)
<i>Augmentin</i>	273	(5)	(4)	-	(41)	>(100)	87	(6)	(1)	186	(5)	(5)
Other anti-bacterials	91	1	2	2	(33)	(33)	26	(11)	(7)	63	9	9
Rare diseases	198	(1)	7	23	(9)	-	66	2	6	109	-	9
Oncology	95	(60)	(60)	-	-	-	-	-	-	95	24	27
Other	256	(18)	(19)	12	(78)	(78)	42	11	20	202	(8)	(10)
<b>Established Products</b>	<b>1,211</b>	<b>(11)</b>	<b>(7)</b>	<b>332</b>	<b>(7)</b>	<b>-</b>	<b>248</b>	<b>(6)</b>	<b>(2)</b>	<b>631</b>	<b>(15)</b>	<b>(12)</b>
<i>Coreg</i>	62	4	11	62	4	11	-	-	-	-	-	-
<i>Hepsera</i>	31	(27)	(22)	-	-	-	-	-	-	31	(27)	(22)
<i>Imigran/Imitrex</i>	77	(12)	(8)	35	(24)	(22)	30	8	15	12	(8)	(8)
<i>Lamictal</i>	290	5	12	148	5	14	50	4	9	92	6	11
<i>Lovaza</i>	23	(60)	(56)	23	(60)	(56)	-	-	-	-	-	-
<i>Requip</i>	55	13	22	8	>100	>100	15	-	7	32	3	7
<i>Serevent</i>	44	(11)	(6)	20	(10)	(5)	18	(11)	(5)	6	(14)	(14)
<i>Seroxat/Paxil</i>	96	5	12	7	>(100)	>(100)	20	12	18	69	(16)	(9)
<i>Valtrex</i>	57	(40)	(35)	9	(18)	(18)	12	(15)	(8)	36	(48)	(44)
<i>Zeffix</i>	59	(21)	(18)	1	-	-	3	-	-	55	(22)	(19)
Other	417	(14)	(12)	19	(19)	(10)	100	(15)	(13)	298	(13)	(12)
	<b>5,874</b>	<b>(7)</b>	<b>(3)</b>	<b>2,113</b>	<b>(7)</b>	<b>-</b>	<b>1,401</b>	<b>(11)</b>	<b>(7)</b>	<b>2,360</b>	<b>(6)</b>	<b>(3)</b>
<b>HIV</b>	<b>1,594</b>	<b>50</b>	<b>59</b>	<b>936</b>	<b>62</b>	<b>74</b>	<b>477</b>	<b>39</b>	<b>46</b>	<b>181</b>	<b>26</b>	<b>28</b>
<i>Combivir</i>	10	(47)	(47)	1	(91)	(90)	3	(37)	(35)	6	(24)	(26)
<i>Epzicom/Kivexa</i>	311	(18)	(14)	111	(17)	(11)	139	(18)	(14)	61	(19)	(18)
<i>Lexiva/Telzir</i>	28	(21)	(18)	15	(28)	(22)	4	(40)	(37)	9	13	10
<i>Selzentry</i>	60	(7)	(2)	30	(1)	7	23	(15)	(11)	7	2	-
<i>Tivicay</i>	413	51	61	272	53	64	104	50	58	37	38	44
<i>Triumeq</i>	737	>100	>100	486	>100	>100	194	>100	>100	57	>100	>100
<i>Trizivir</i>	9	(43)	(36)	2	(49)	(46)	5	(36)	(33)	2	(61)	(26)
Other	26	(5)	(10)	19	(3)	5	5	(15)	(12)	2	(8)	(55)
<b>Pharmaceuticals</b>	<b>7,468</b>	<b>1</b>	<b>6</b>	<b>3,049</b>	<b>7</b>	<b>16</b>	<b>1,878</b>	<b>(2)</b>	<b>2</b>	<b>2,541</b>	<b>(4)</b>	<b>(2)</b>

**Vaccines turnover – six months ended 30 June 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Rotarix</i>	217	4	9	60	(10)	(3)	35	6	9	122	10	16
<i>Synflorix</i>	228	58	66	-	-	-	22	24	29	206	63	72
<i>Fluarix, FluLaval</i>	26	>100	>100	-	-	-	-	-	-	26	>100	>100
<i>Bexsero</i>	159	>100	>100	47	>100	>100	101	>100	>100	11	>100	>100
<i>Menveo</i>	89	61	65	56	40	75	18	>100	>100	15	29	7
<i>Boostrix</i>	184	7	14	91	(6)	2	67	33	40	26	4	4
<i>Infanrix, Pediarix</i>	328	(16)	(12)	131	(9)	(2)	155	(6)	(2)	42	(48)	(49)
Hepatitis	266	(4)	1	118	(10)	(3)	98	21	26	50	(22)	(22)
<i>Priorix, Priorix Tetra, Varilrix</i>	142	20	24	-	-	-	78	18	25	64	23	24
<i>Cervarix</i>	34	(26)	(26)	1	(50)	(50)	15	(26)	(21)	18	(24)	(28)
Other	169	39	46	16	(13)	-	75	61	65	78	37	43
	<b>1,842</b>	<b>16</b>	<b>22</b>	<b>520</b>	<b>5</b>	<b>14</b>	<b>664</b>	<b>28</b>	<b>33</b>	<b>658</b>	<b>15</b>	<b>18</b>